Trending
Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024
We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...
Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs: What Does This Mean For Pharma Companies?
Alex Azar, Secretary of Health and Human Services (HHS), made a significant game-changing announcement to prescription drug pricing during the federal government shutdown that received little attention in the popular press. In short, the proposed rule would eliminate rebates to pharmacy benefit managers (PBMs) in the Medicare and Medicaid programs by January 1, 2020. This change from the Trump ...
Perspectives On Pharma Company Use Of Open Payments Data
The creation of Open Payments Data (OPD) was formed from the Affordable Care Act to bring greater public transparency to the financial relationships between pharma and medical device companies, and healthcare providers. This white paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies, and ...
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
Orphan drugs (ODs) for rare diseases (RDs) present pharma companies with the opportunity to address a substantial unmet medical need, with approximately 7,000 RDs and only about 5% having effective treatments. A large number of patients in the US are affected by these RDs (around 25-30 million people). The majority of RDs affect children. Also, RDs often translate into chronic and deteriorating ...
Growing Attention Being Paid To Pharma Company Rebates And Discounts
Drug company rebates and discounts have always been an opaque aspect of the US pharma industry. There is little transparency in how much drug companies pay in rebates and discounts. Indications are it is annually in the tens of billions of dollars for the industry and growing. Price concessions can significantly vary by individual company depending on the portfolio mix and individual therapy ...
How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?
The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, and Republicans expanding their majority in the Senate. Will there be bipartisan collaboration or political conflict and policy immobilism? This paper provides a detailed analysis why the US pharma industry, specifically ...
Is The CVS-Aetna Merger A Pharma Industry Transformative Event?
US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Express Scripts merger, and partnering activities by Amazon, Berkshire Hathaway, and J.P. Morgan to get into the healthcare industry. These events taken together suggest what some have characterized as “the era of retail ...
Deploying Successful Global Incentive Compensation Capabilities
Companies spend between 10% and 40% of their total revenue on their sales force - Bain, Frontline of Healthcare Report Over 70% organizations feel their employees do not understand the compensation philosophy - workatwork.org Incentive Compensation (IC) can single-handedly make or break your sales force. It’s a process that sales and commercial leaders constantly strive to get right and implement ...
Aligning Sales To The Field Force – Increasing Complexities With Change In The Pharma Landscape
Sales Crediting – a challenge most companies feel today with the increasing complexity of the market! Even more complex is the task of deciphering the downstream impact on incentive compensation and further impact on the sales reps’ motivation because of false crediting. With this whitepaper, unravel the means of actual and correct sales crediting and therefore, reduce pitfalls in incentive ...
The Value Of Machine Learning And Data Mining In Pharmaceutical Commercial Analytics
It is widely believed that machine learning and data mining are right on the cusp of becoming among the most important breakthroughs that the healthcare industry has seen in years. While applications of these techniques have already occurred elsewhere in the pharma sector, wide-spread applications in pharmaceutical commercial analytics have come more recently. Pharma companies are now looking to ...